Involution of classic Kaposi sarcoma lesions under acitretin treatment Kaposi sarcoma treated with acitretin

Daadaa, N.; Souissi, A.; Chaabani, M.; Chelly, Inès; Salem, Moez Ben; Mokni, M.

doi:10.1002/ccr3.3428

Cited by 3 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 24 Interestingly, a case report by Daadaa et al , revealed the efficacy of acitretin as a treatment for KS. 26 However, to our knowledge there is currently no literature available discussing the efficacy of retinoic acid in treating KS with concurrent CTCL.…”

Section: Discussionmentioning

confidence: 99%

Concurrent development of HIV-negative Kaposi’s sarcoma and mycosis fungoides in an elderly Inuit from Canada

et al. 2021

View full text Add to dashboard Cite

An 88-year-old Inuit man from Northern Canada presented with an extensive skin rash associated with numerous violaceous skin nodules on his palms and lower extremities. Biopsy of a skin nodule revealed Kaposi’s sarcoma (KS), a human herpesvirus 8 (HHV8)-associated malignancy, whereas biopsy of the erythematous skin showed an atypical infiltrate of CD4-positive T-cells that, together with TCR gene rearrangement and presence of clonal T-cells in peripheral blood by flow cytometry, was consistent with a T-cell lymphoma, mycosis fungoides (MF) subtype. Serology was negative for HIV and HTLV-I/II and no immunodeficiency syndrome was identified. The patient was successfully treated with an oral retinoid for KS, and with topical hydrocortisone and ultraviolet B (UVB) phototherapy for MF. This case highlights the existence of HHV8-related lesions in native persons of Northern Canada, and also that MF-induced immunosuppression combined with immunosenescence may play a role in the development of non-HIV-related KS.

show abstract

Section: Discussionmentioning

confidence: 99%

Concurrent development of HIV-negative Kaposi’s sarcoma and mycosis fungoides in an elderly Inuit from Canada

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Aditionally, 0.1% alitretinoin is being considered for off-label use in treating non-AIDS related Kaposi's sarcoma (KS), given its reported effectiveness. 19 Although not commonly used in clinical practice, oral acitretin has been successful in treating classic KS unrelated to HIV. 19…”

Section: Kaposi Sarcoma Treatmentmentioning

confidence: 99%

“…19 Although not commonly used in clinical practice, oral acitretin has been successful in treating classic KS unrelated to HIV. 19…”

Section: Kaposi Sarcoma Treatmentmentioning

confidence: 99%

Retinoids in Skin Cancer Chemoprophylaxis and Treatment

Tran Thi,

Nguyen Huu

2024

TC DLH VN

View full text Add to dashboard Cite

Skin cancer is the most common type of cancer in the United States. There are 2 main types of skin cancer: melanoma and non-melanoma. The 2 most common types of non-melanoma skin cancer are called basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Some other less common non-melanoma cancers including cutaneous T lymphoma (CTCL), Kaposi sarcoma (KS),…1 Factors that increase the risk of skin cancer include ultraviolet radiation, skin type, gene factor, virus infection, immunodeficiency, and chemical substance,… Among them, ultraviolet radiation is one of the most emphasized factors. Received 28 June 2023Revised 26 September 2023Accepted 29 November 2023

show abstract

“…Notably, 0.1% alitretinoin is considered for use off-label to treat non-AIDS related KS, based on the documented success [ 275 ]. Oral acitretin has also been used to treat classic KS (unrelated to HIV) successfully, although not typically used clinically [ 276 ].…”

Section: The Use Of Retinoids For Skin Cancer Treatmentmentioning

confidence: 99%

The Use of Retinoids for the Prevention and Treatment of Skin Cancers: An Updated Review

Ramchatesingh

Villarreal

Arcuri

et al. 2022

IJMS

View full text Add to dashboard Cite

Retinoids are natural and synthetic vitamin A derivatives that are effective for the prevention and the treatment of non-melanoma skin cancers (NMSC). NMSCs constitute a heterogenous group of non-melanocyte-derived skin cancers that impose substantial burdens on patients and healthcare systems. They include entities such as basal cell carcinoma and cutaneous squamous cell carcinoma (collectively called keratinocyte carcinomas), cutaneous lymphomas and Kaposi’s sarcoma among others. The retinoid signaling pathway plays influential roles in skin physiology and pathology. These compounds regulate diverse biological processes within the skin, including proliferation, differentiation, angiogenesis and immune regulation. Collectively, retinoids can suppress skin carcinogenesis. Both topical and systemic retinoids have been investigated in clinical trials as NMSC prophylactics and treatments. Desirable efficacy and tolerability in clinical trials have prompted health regulatory bodies to approve the use of retinoids for NMSC management. Acceptable off-label uses of these compounds as drugs for skin cancers are also described. This review is a comprehensive outline on the biochemistry of retinoids, their activities in the skin, their effects on cancer cells and their adoption in clinical practice.

show abstract

Involution of classic Kaposi sarcoma lesions under acitretin treatment Kaposi sarcoma treated with acitretin

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 3 publications

References 12 publications

Concurrent development of HIV-negative Kaposi’s sarcoma and mycosis fungoides in an elderly Inuit from Canada

Concurrent development of HIV-negative Kaposi’s sarcoma and mycosis fungoides in an elderly Inuit from Canada

Retinoids in Skin Cancer Chemoprophylaxis and Treatment

The Use of Retinoids for the Prevention and Treatment of Skin Cancers: An Updated Review

Contact Info

Product

Resources

About